Clinical trial
Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive…
NCT00464776 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00464776 |
|---|---|
| Title | Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy |
| Official title | A Randomized, Double-blind, Cross-over, 4-period, 4 Treatment, Within-subject Placebo-controlled Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Type 2 Diabetic Patients With Incipient or Overt Nephropathy |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Aliskiren |
| Enrollment | 26 |
| Start date | Oct 1, 2005 |
| Primary completion | Apr 1, 2008 |
| First posted | Apr 24, 2007 |
| Last update posted | Feb 4, 2011 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: